Ketoprofen controlled release from composite microcapsules for cell encapsulation: effect on post-transplant acute...

Area of Science:

• Biomaterials Science
• Immunology
• Regenerative Medicine

Background:

• Cell encapsulation is crucial for Type 1 diabetes treatment, but graft survival is limited by inflammation.
• Existing encapsulated islet strategies face challenges including biocompatibility, immune rejection, hypoxia, and poor beta-cell replication.

Purpose of the Study:

• To design and evaluate composite microcapsules for preventing early-stage inflammatory responses post-implantation.
• To assess the biocompatibility and efficacy of biodegradable microspheres containing ketoprofen within alginate-based capsules.

Main Methods:

• Biodegradable polyester microspheres loaded with ketoprofen were prepared using solvent evaporation.
• These microspheres were encapsulated within alginate/poly-L-ornithine/alginate capsules.
• In vivo studies assessed biocompatibility and the prevention of inflammatory responses.

Main Results:

• Successful preparation of microspheres with good encapsulation efficiency and desired particle size.
• In vitro release studies indicated a significant initial burst release of ketoprofen.
• The composite microcapsules demonstrated excellent biocompatibility and completely prevented inflammatory responses and pericapsular overgrowth.

Conclusions:

• Multicompartment microcapsules releasing non-steroidal anti-inflammatory drugs can circumvent the immediate post-transplant inflammatory response.
• This strategy holds promise for improving the long-term success of encapsulated islet transplantation.